Remove Genetic Disease Remove RNA Remove Vaccination
article thumbnail

Merck and Orna partner for RNA technology-based vaccines and therapies

Pharmaceutical Technology

Merck (MSD outside North America) has entered a partnership agreement with Orna Therapeutics for discovering, developing and marketing various programmes based on next-generation RNA technology. These programmes will include therapies and vaccines in infectious disease and oncology areas.

RNA 147
article thumbnail

General Design Methods for mRNA Drugs

Pharma Mirror

With the rapid development of biotechnology and molecular medicine, the introduction of mRNA as a vaccine or therapeutic agent enables the production of almost any desired functional protein/peptide within the human body.

In-Vitro 130
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Eli Lilly Pursues RNA Editing in New Partnership with ProQR

XTalks

With RNA therapies being the next hot thing in genetic medicine, Eli Lilly is joining the RNA editing race by partnering with Netherlands-based ProQR Therapeutics NV (Nasdaq: PRQR), a biotech company developing RNA-based therapies for rare genetic diseases with a focus on blinding disorders of the retina.

RNA 104
article thumbnail

Shape Therapeutics-Roche’s Deal; AllStripes Raises $50M; Datavant-Real Chemistry’s Partnership; BlueWillow’s Nasal Vaccine

Delveinsight

Seattle biotech firm Shape Therapeutics has signed a deal potentially exceeding USD 3 billion with pharma giant Roche to bolster the development of gene therapies for Alzheimer’s and Parkinson’s disease. Shape’s RNA editing technologies can modify the RNA sequence, which makes the body’s protein building blocks.

article thumbnail

Beyond the pandemic: the potential of mRNA technology

pharmaphorum

The arrival of COVID-19 brought precious few positives, but one that emerged for the pharmaceutical industry was the emergence and validation of mRNA vaccine technology to prevent disease. Pfizer already has a head start on competitors in the field, having achieved the first US FDA approval for an mRNA vaccine, alongside BioNTech.

RNA 111
article thumbnail

FDA and CDC Update Guidelines Amid Omicron + Life Science Trends for 2022 – Xtalks Life Science Podcast Ep. 42

XTalks

In the first episode of 2022, Ayesha provided updates on Omicron and COVID-19 vaccine boosters. These include the continued promise of RNA-based vaccines as well as therapeutics based on RNA editing approaches for the treatment of various conditions including rare genetic diseases.

article thumbnail

Key Trends in the Life Sciences to Look Forward to in 2022

XTalks

The RNA Revolution: From mRNA Vaccines to RNA Editing. The age of RNA is officially here, and it’s here to stay as more than a passing life science trend. The power of its real-world application was demonstrated by the resounding success of the mRNA COVID-19 vaccines. RNA in the Making.